Condition
SSc-Systemic Sclerosis clinical trials and research
As of November 12, 2026, Find a Trial lists 4 SSc-Systemic Sclerosis clinical trials that are recruiting, at sites in 2 countries (most in China (3), Greece (1)). By phase: Early Phase 1 (2), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 2Countries
Newest SSc-Systemic Sclerosis clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Dual immunosuppression alone versus dual immunosuppression plus antifibrotic for scleroderma-related interstitial lung disease | — | Pátrai | Recruiting | Mar 24, 2026 |
| CT1195E CAR-T cell therapy for refractory or progressive systemic sclerosis | Early Phase 1 | Wuhan, Hubei | Recruiting | Jan 21, 2026 |
| Dual-target CAR T therapy (CD19 and BCMA) for relapsed or treatment-resistant autoimmune diseases | Phase 1 | Tianjin | Recruiting | Jan 2, 2026 |
| CC312 for relapsed or treatment‑resistant lupus, inflammatory myopathies, and systemic sclerosis | Early Phase 1 | Deyang, Sichuan | Recruiting | Sep 26, 2025 |
All recruiting trials (4)
-
Dual immunosuppression alone versus dual immunosuppression plus antifibrotic for scleroderma-related interstitial lung disease
This project will test whether adding an antifibrotic drug to dual immunosuppression helps people with scleroderma-related interstitial lung disease.
-
CT1195E CAR-T cell therapy for refractory or progressive systemic sclerosis
This trial will test whether CT1195E CAR-T cell therapy is safe and helps adults (18–60) with refractory or progressive systemic sclerosis.
-
Dual-target CAR T therapy (CD19 and BCMA) for relapsed or treatment-resistant autoimmune diseases
This will try a single infusion of off-the-shelf (allogeneic) CAR T-cells that target CD19 and BCMA in adults whose autoimmune disease has relapsed or not responded to other treatments.
-
CC312 for relapsed or treatment‑resistant lupus, inflammatory myopathies, and systemic sclerosis
This early-phase test will try CC312 to see if it is safe and may help adults aged 18–65 with relapsed or treatment‑resistant systemic lupus erythematosus, idiopathic inflammatory myopathies, or systemic sclerosis.
Related topics
Quick answers
How many SSc-Systemic Sclerosis clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in China (3 trials), Greece (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Early Phase 1: 2, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.